Abiopharma

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

X-energy, SGL Carbon Announce Capacity Expansion for Nuclear-Grade Graphite

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Second Quarter 2026 Resultsate Report

Aurora Mobiles GPTBots.ai Launches LoopAgent: Production-Grade Execution That Runs Complex Tasks End-to-End

Luckin Coffee Announces Second Quarter 2026 Financial Results

Liberty Global Completes Buyout of VodafoneZiggo as it Prepares for 2027 Ziggo Group Listing

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights